Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
Summary
- Conditions
- Chronic Obstructive Pulmonary Disease - COPD
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentMasking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 40 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01551888
- Collaborators
- Not Provided
- Investigators
- Study Director: Esther Garcia, MD AstraZeneca
Get Well Soon